version française rss feed
.:. Consulter > Par domaine > Cancer .:.
32 documents classés par : 
1 - 2 - 3 - 4 Page Suivante Page Finale
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
Robinson S.P., Canals C., Luang J.J., Tilly H., Crawley C., Cahn J.Y., Pohlreich D., Le Gouill S., Gilleece M., Milpied N. et al
Bone Marrow Transplantation (2013) epub ahead of print [hal-00849676 - version 1]
restricted file access (Functional magnetic resonance imaging. What are the benefits expected in hand surgery?).
Moutet F., Delon-Martin C., Martin O., Sirigu A., Delaquaize F., Benali H., Masquelet A.-C.
Chirurgie de la Main 32, 3 (2013) 121-8 [inserm-00861214 - version 1]
Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.
Weitz I., Meyers G., Lamy T., Cahn J.-Y., Uranga M.T., García Vela J.A., Sanz M.A., Severino B., Kelly R.J., Hillmen P. et al
Internal Medicine Journal 43, 3 (2013) 298-307 [hal-00849689 - version 1]
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Tanguy-Schmidt A., Rousselot P., Chalandon Y., Cayuela J.-M., Hayette S., Vekemans M.-C., Escoffre M., Huguet F., Réa D., Delannoy A. et al
Biology of Blood and Marrow Transplantation 19, 1 (2013) 150-5 [hal-00849684 - version 1]
Evaluation of tourists' UV exposure in Paris
Mahé E., Corrêa M.P., Godin-Beekmann S., Haeffelin M., Jégou F., Saiag P., Beauchet A.
Journal of the European Academy of Dermatology and Venereology 27, 3 (2013) e294-e304 [hal-00875016 - version 1]
fulltext access Modélisation et étude histologique de gliomes diffus de bas grade
Gerin C.
Université Paris-Diderot - Paris VII (24/09/2012), Mathilde Badoual (Dir.) [tel-00820353 - version 2]
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
Ballen K. K., Woolfrey A. E., Zhu X., Ahn K. W., Wirk B., Arora M., George B., Savani B. N., Bolwell B., Porter D. L. et al
Biology of Blood and Marrow Transplantation 18, 9 (2012) 1446-54 [hal-00849698 - version 1]
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I., Cadranel J., Pignon J.-P., Quoix E., Coudert B., Westeel V., Dansin E., Madelaine J., Madroszyk A., Friard S. et al
European Respiratory Journal 39, 1 (2012) 172-179 [hal-00682873 - version 1]
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Löwenberg B., Muus P., Ossenkoppele G., Rousselot P., Cahn J.-Y., Ifrah N., Martinelli G., Amadori S., Berman E., Sonneveld P. et al
Blood 118, 23 (2011) 6030-6 [hal-00849706 - version 1]
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs.
Emile J.F., Brahimi S., Coindre J.M., Bringuier P.P., Monges G., Samb P., Doucet L., Hostein I., Landi B., Buisine M.P. et al
Medical Oncology (2011) epub ahead of print [hal-00636301 - version 1]